ORAL PRESENTATION



Open Access

Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD-scintigraphy

Ludivine Eliahou^{1*}, Renata Chequer², Phalla Ou³, Vincent Algalarrondo⁴, Teresa Antonini⁵, Michel Slama⁶, Dominique Le Guludec⁷, François Rouzet⁸

From First European Congress on Hereditary ATTR amyloidosis Paris, France. 2-3 November 2015

Background

Three main imaging techniques are commonly used to identify cardiac transthyretin (ATTR) amyloidosis: echocardiography, MRI and DPD scintigraphy. Each one provides specific diagnostic and prognostic informations but also has its specific limitations. We sought to evaluate a multimodality imaging strategy to diagnose cardiac amyloidosis in ATTR.

Methods

Seventy seven consecutive patients with multimodality imaging evaluation (echocardiography, 1.5T MRI and 99mTc-DPD scintigraphy) to diagnose cardiac amyloidosis were identified from the database of the French National Reference Center for Amyloidosis. Patients with pacemaker or severe renal failure did not undergo cardiac MRI and were analyzed on the basis of the echocardiography and scintigraphy (n=17). Three groups were compared: patients with positive agreement to diagnose cardiac ATTR (PA-ATTR group), patients with positive agreement to exclude cardiac ATTR (PA-normal) and patients with negative agreement (NA).

Results

The mean age was 52 years [44-70]; 59% were male. Transthyretin mutations were Val30Met in 67%, other in 21%, and 12% had acquired ATTR from previous domino liver transplantation; 30 patients had a positive echocardiography, 37 positive MRI and 36 positive DPD scintigraphy. Positive imaging agreement was encountered in

¹Hopital Antoine Béclère, Cardiologie, French Referent Center for Rare Diseases for FAP (Familial Amyloid Polyneuropathy) (NNERF), 92140, Clamart, France

Full list of author information is available at the end of the article

50/77 patients (65%: 30 PA-ATTR and 20 PA-normal). Negative agreement was observed in 27/77 patients (35%). Compared with PA-ATTR patients, NA patients were younger (68 [64-72] years vs. 46 [41-64], had lower BNP levels (149 [94-248] pg/ml vs. 40 [25-102],) and thinner interventricular septum (17 [14-20] mm vs. 12 [10-14]), all p values <0.0001). The two main causes for negative agreement between techniques was the sole positivity of the MRI (n=10) and the sole negativity of the DPD scintigraphy(n=6). Compared with PA-ATTR patients, patients with a sole MRI positivity were younger (41 [39-44] years vs. 68 [64-72] p<0.001), more frequently women (80% vs.26% p=0,002), had thinner interventricular septum (9 [8-11] mm vs.17 [14-20], p<0.0001), had lower BNP levels (26 [24-36] vs 149 [92-249] p<0.0001) and had less diffuse late gadolinium enhancement pattern (10% vs. 66% patients; p<0.0001). As compared with PA-ATTR patients, patients with a sole negativity of the DPD scintigraphy had acquired ATTR from domino liver transplantation in all but one case (83% vs. 6% patients; p=0.02).

Conclusions

In transthyretin amyloidosis, the agreement between echocardiography, cardiac MRI and DPD scintigraphy to diagnose cardiac amyloidosis was observed in 65% of patients. Patients without agreement between these three techniques had distinct patterns of cardiac involvement: sole positivity of the MRI was encountered in patients in the early stages of ATTR; patients with acquired ATTR due to domino liver transplantation often had negative DPD scintigraphy.



© 2015 Eliahou et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors' details

 ¹Hopital Antoine Béclère, Cardiologie, French Referent Center for Rare Diseases for FAP (Familial Amyloid Polyneuropathy) (NNERF), 92140, Clamart, France. ²Hopital Bichat-Claude Bernard, Médecine Nucléaire, 75018, Paris, France. ³Hopital Bichat-Claude Bernard, Radiologie, 75018, Paris, France.
⁴Hopital Antoine Béclère, Cardiologie, French Referent Center for Rare Diseases for FAP (Familial Amyloid Polyneuropathy), 92140, Clamart, France.
⁵Hopital Paul Brousse, Centre Hépato-Biliaire, 94800, Villejuif, France. ⁶Hopital Antoine Béclère, Cardiologie,French Referent Center for Rare Diseases for FAP (Familial Amyloid Polyneuropathy), 92140, Clamart, France. ⁷Hopital Bichat-Claude Bernard, Médecine Nucléaire, 75018, Paris, France. ⁸Hopital Bichat-Claude Bernard, Médecine Nucléaire, 75018, Paris, France.

Published: 2 November 2015

doi:10.1186/1750-1172-10-S1-O17

Cite this article as: Eliahou *et al.*: **Multi-modality imaging in cardiac ATTR** amyloidosis: agreement between echocardiography, MRI and DPDscintigraphy. *Orphanet Journal of Rare Diseases* 2015 **10**(Suppl 1):O17.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

BioMed Central